Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics
- PMID: 19460280
- DOI: 10.6004/jnccn.2009.0037
Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics
Abstract
Carcinosarcoma of the uterus (malignant mixed Müllerian tumor [MMMT]) is an uncommon, typically extremely aggressive neoplasm histologically composed of malignant epithelial and mesenchymal (stromal) elements. Although the literature contains some debate, most authors now agree that most MMMTs derive from sarcomatous differentiation in a high-grade carcinoma. This article reviews the clinical and histopathologic features of this interesting neoplasm, with particular emphasis on recent data supporting MMMTs as primarily epithelial malignant neoplasms with areas of mesenchymal/spindle cell differentiation.
Similar articles
-
Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.Int J Gynecol Pathol. 2017 Sep;36(5):412-419. doi: 10.1097/PGP.0000000000000346. Int J Gynecol Pathol. 2017. PMID: 28700424
-
CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711. Stem Cells. 2011. PMID: 21919130
-
Pathology of mixed Müllerian tumours.Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):705-18. doi: 10.1016/j.bpobgyn.2011.05.010. Epub 2011 Jul 13. Best Pract Res Clin Obstet Gynaecol. 2011. PMID: 21742560 Review.
-
Eight cases of malignant mixed Müllerian tumor (carcinosarcoma) of the uterus: findings in SurePath™ cervical cytology.Diagn Cytopathol. 2014 Feb;42(2):165-9. doi: 10.1002/dc.22910. Epub 2012 Aug 4. Diagn Cytopathol. 2014. PMID: 22865798
-
Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90. doi: 10.1136/ijgc-00009577-200211000-00001. Int J Gynecol Cancer. 2002. PMID: 12445244 Review.
Cited by
-
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?J Cancer Res Clin Oncol. 2020 Mar;146(3):695-704. doi: 10.1007/s00432-019-03091-y. Epub 2020 Jan 28. J Cancer Res Clin Oncol. 2020. PMID: 31993743 Free PMC article.
-
Loss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma.Cancer Sci. 2025 Mar;116(3):835-845. doi: 10.1111/cas.16423. Epub 2024 Dec 23. Cancer Sci. 2025. PMID: 39716847 Free PMC article.
-
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.Balkan Med J. 2016 Sep;33(5):517-524. doi: 10.5152/balkanmedj.2016.151268. Epub 2016 Sep 1. Balkan Med J. 2016. PMID: 27761279 Free PMC article.
-
Carcinosarcoma of the Endometrium-Pathology, Molecular Landscape and Novel Therapeutic Approaches.Medicina (Kaunas). 2025 Jun 26;61(7):1156. doi: 10.3390/medicina61071156. Medicina (Kaunas). 2025. PMID: 40731786 Free PMC article. Review.
-
Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment.Cancers (Basel). 2022 Sep 14;14(18):4465. doi: 10.3390/cancers14184465. Cancers (Basel). 2022. PMID: 36139624 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical